Madrigal Pharmaceuticals drew fresh attention after publishing a secondary analysis of its Phase 3 MAESTRO-NASH trial, indicating that Rezdiffra's liver benefits appeared consistent across several common MASH genetic risk variants. The company's shares have eased in recent months, down 9.86% on a 30 day basis and 17.87% year to date, though the 1 year total shareholder return of 11.62% and a 5 year total shareholder return near 6x suggest longer term momentum has remained strong. Madrigal last closed at $487.72, while the most widely followed fair value narrative sits higher at $678.71 based on a 7.16% discount rate, a gap that keeps attention on how Rezdiffra and its MASH footprint could support the valuation story. The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity. The story could still change quickly if Rezdiffra underwhelms in later stage data, or if rivals and payer pushback squeeze long term uptake.
Madrigal Pharmaceuticals IncSecondary analysis of Phase 3 MAESTRO-NASH shows Rezdiffra's liver benefits consistent across common MASH genetic risk variants, supporting the drug's clinical profile.
